Repurposed Drugs, Metabolic Modulation, and Micronutrients for Cancer (2020–2026 Evidence): Emerging Adjunct Therapies
Abstract
Cancer therapy is increasingly exploring adjunct strategies beyond conventional treatments to improve outcomes and patient quality of life. Recent evidence (2020–2026) highlights the potential of repurposed antiparasitic drugs—notably ivermectin, mebendazole, and fenbendazole—for their anti-proliferative, pro-apoptotic, and anti-metastatic effects. Metabolic interventions, including ketogenic diets, intermittent fasting, and mitochondrial-targeted therapies, further disrupt tumor energy metabolism and enhance treatment efficacy. Concurrently, micronutrient support with vitamins C and D, as well as zinc, demonstrates immune modulation, oxidative stress reduction, and synergistic anti-cancer activity. Integrating these approaches offers a multifaceted framework targeting cancer stem cells, tumor metabolism, and immune function. While preclinical and early clinical data are promising, rigorous trials are required to establish safety, optimal dosing, and long-term efficacy. This review synthesizes current evidence, providing a roadmap for precision adjunctive oncology that combines pharmacologic repurposing, metabolic modulation, and targeted micronutrients.Keywords: cancer, repurposed drugs, ivermectin, mebendazole, fenbendazole, ketogenic diet, intermittent fasting, vitamins C and D, zinc, adjunct therapy, precision oncology
.png "Repurposed Drugs and Natural Compounds in Cancer")
Introduction
Cancer remains a leading cause of morbidity and mortality worldwide, with ongoing research exploring novel adjunct therapies beyond conventional chemotherapy and radiotherapy. Recent studies highlight the repurposing of antiparasitic drugs, dietary and metabolic interventions, and micronutrient modulation as promising strategies to enhance cancer treatment outcomes and improve patient quality of life (Adapa et al., 2024; Arora et al., 2023; Ashique et al., 2023).
Repurposed Antiparasitic Drugs in Cancer Therapy
Ivermectin and mebendazole, and their potential role in cancer treatment have sparked significant interest online. Through our research, we've observed that most studies available are case reports and preclinical studies, with a notable lack of published randomised controlled clinical studies.
Ivermectin
Ivermectin, historically used for parasitic infections, has demonstrated anti-tumor activity through multiple mechanisms, including inhibition of the Wnt/β-catenin pathway, suppression of metastasis, and promotion of apoptosis in cancer stem cells (Jiang et al., 2022; Juarez et al., 2020). Preclinical studies and early clinical evaluations suggest that continuous high-dose ivermectin is safe in specific populations, supporting its repurposing potential (de Castro et al., 2020).
Mebendazole and Fenbendazole
Benzimidazole derivatives, such as mebendazole and fenbendazole, exhibit broad-spectrum anti-cancer effects. Mechanisms include disruption of microtubule dynamics, inhibition of proliferation, and overcoming chemoresistance, particularly in ovarian cancer cells (Huang et al., 2021; Chai et al., 2021; Chiang et al., 2021). Case series indicate potential synergistic benefits when combined with conventional therapies.
Synergistic Approaches
Combining these agents with metabolic therapies and micronutrients enhances their efficacy. For example, dichloroacetate paired with ivermectin shows potentiated anti-tumor effects by altering cellular energy metabolism (Ishiguro et al., 2022).
Metabolic Interventions
Ketogenic Diet and Intermittent Fasting
Metabolic therapies targeting tumor energy metabolism are gaining traction. Ketogenic diets restrict glucose availability, increasing oxidative stress in cancer cells and reducing proliferation and stemness (Ji et al., 2020; Flockhart et al., 2021). Similarly, intermittent fasting modulates autophagy and may improve responses to standard therapies (Arora et al., 2023). These interventions demonstrate enhanced mitochondrial function and ROS-mediated tumor suppression, positioning them as viable adjuncts.
Mitochondrial Modulation
Mitochondrial health is critical for cancer progression and treatment resistance. Therapies that restore or manipulate mitochondrial function, such as methylene blue metabolic therapy, have shown promise in preclinical ovarian tumor models (da Veiga Moreira et al., 2024).
Micronutrient Support
Vitamin C
Vitamin C exerts pro-oxidant effects at pharmacologic doses, selectively targeting cancer cells and enhancing apoptosis (Fan et al., 2023). Evidence supports its role in combination with chemotherapy, metabolic therapies, and repurposed drugs to improve treatment outcomes (Ashique et al., 2023).
Vitamin D
Vitamin D supplementation, particularly in patients with digestive tract cancers, has demonstrated reduced relapse and mortality in specific subgroups, highlighting its role in precision oncology (Kanno et al., 2023). Additionally, vitamin D improves immune modulation and may synergize with standard therapies (Bull et al., 2020; Hillers-Ziemer et al., 2020).
Zinc
Zinc supports immune function, oxidative balance, and apoptosis of cancer cells, making it a valuable adjunct in cancer management. Recent systematic reviews confirm its role in improving patient outcomes and reducing treatment-related complications (Hoppe et al., 2021; Aljohar et al., 2022; Gelbard, 2022).
Integrated Therapeutic Framework
Combining repurposed drugs, metabolic interventions, and micronutrient supplementation offers a multifaceted approach to cancer care. This framework targets:
Cancer stem cells – disrupting self-renewal and survival (Chai et al., 2021; Jariyal et al., 2021).
Tumor metabolism – ketogenic diets, fasting, and mitochondrial therapies reduce energy supply and enhance oxidative stress (Ji et al., 2020; da Veiga Moreira et al., 2024).
Immune modulation and oxidative support – vitamins C, D, and zinc enhance apoptosis and reduce inflammation (Ashique et al., 2023; Kanno et al., 2023).
This integrative strategy aligns with the emerging focus on precision oncology, emphasizing tailored, evidence-based adjunct therapies that complement conventional treatment while maintaining patient safety.
Safety and Clinical Considerations
While preclinical and early clinical evidence is promising, it is critical to:
Monitor drug-drug and nutrient interactions (ANSM, 2023).
Adjust dosing based on patient-specific metabolism and comorbidities (Deligiorgi et al., 2020).
Conduct controlled clinical trials to validate efficacy and long-term safety for repurposed agents in oncology (Juarez et al., 2020; de Castro et al., 2020).
Conclusion
Emerging data from 2020–2026 suggest that repurposed antiparasitic drugs, metabolic modulation, and targeted micronutrients constitute a promising adjunctive framework for cancer therapy. This approach addresses cancer stem cell dynamics, tumor metabolism, and immune support, potentially improving treatment response, reducing relapse, and enhancing overall quality of life. Future research should focus on rigorous clinical trials and integrative protocols to translate these findings into standard oncology practice.
References (2020–2026)
1. Repurposed Antiparasitic Drugs (Ivermectin, Mebendazole, Fenbendazole)
Clinical / Human Evidence
Mansoori, S., Fryknäs, M., Alvfors, C., Loskog, A., Larsson, R., and Nygren, P. (2021). “A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer.” Sci Rep. 11(1): 8981. https://doi.org/10.1038/s41598-021-88433-y. (Nature 2021)
de Castro, C. G. Jr., et al. (2020) – “High-dose ivermectin in acute myelogenous leukemia.” Leuk Lymphoma., 61(10): 2536-2537. https://doi.org/10.1080/10428194.2020.1786559
Chiang, R., et al. (2021) – “Fenbendazole enhancing anti-tumor effect: A case series.” Clin Oncol Case Rep., 4(2) (pdf)
Ishiguro, T., Ishiguro, R. H., Ishiguro, M., Toki, A., and Terunuma, H. (2022). “Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin.” Cureus. 14(2): e21884. https://doi.org/10.7759/cureus.21884.
Feng, Y., et al. (2022) – Ivermectin + autophagy (glioma)
Lee, D. E., et al. (2022) – Ivermectin + gemcitabine (pancreatic cancer)
Jiang, L., et al. (2022) – Ivermectin anti-metastasis signaling
Li, N., et al. (2020) – Proteomics + ivermectin metabolism
Tang, M., et al. (2021) – Ivermectin anticancer review
Liu, J., et al. (2020) – Mechanisms of ivermectin
Son, D. S., et al. (2020) – Benzimidazoles as anticancer agents
Song, B., et al. (2022) – Repurposing benzimidazoles
Chai, J. Y., et al. (2021) – Albendazole/mebendazole update
2. Metabolic Therapy (Ketogenic Diet, Fasting, Mitochondria)
Arora, N., et al. (2023) – IF + ketogenic diet (clinical nutrition)
Phillips, M. C. L., et al. (2022) – Metabolic therapy case series (glioblastoma)
Ji, C. C., et al. (2020) – Ketogenic diet + glioma stem cells
Seyfried, T. N., et al. (2020) – ATP origin in cancer
Seyfried, T. N. & Chinopoulos (2021) – Metabolic theory of cancer
Deligiorgi, M. V., et al. (2020) – Fasting as anticancer therapy
Tiwari, S., et al. (2022) – Fasting review
Weber, D. D., et al. (2020) – Ketogenic diet in cancer
Martinez, P., et al. (2024) – Mitochondria–stem cell link
Liu, Y., et al. (2023) – Mitochondria in cancer metabolism
3. Vitamin C (Ascorbate Therapy)
Roa, F. J., et al. (2020) – Therapeutic use review (clinical relevance)
Long, Y., et al. (2021) – Glutamine targeting cancers
Wan, J., et al. (2021) – Liver cancer inhibition
Ma, Z., et al. (2022) – Vitamin C immunotherapy (macrophages)
Luo, X., et al. (2022) – Inflammation/metabolic protection
Yu, C., et al. (2023) – Warburg effect inhibition
Butt, G., et al. (2020)
Satheesh, N. J., et al. (2020)
Fan, D., et al. (2023)
Lee, Y. (2023)
4. Vitamin D & Cancer
Chandler, P. D., et al. (2020) – VITAL trial (advanced cancer)
Kanno, K., et al. (2023) – AMATERASU subgroup analysis. “Vitamin D supplements reduce relapse in digestive tract cancer.” JAMA Netw Open., 6(8): e2328886. https://doi.org/10.1001/jamanetworkopen.2023.28886
Keum, N., et al. (2022) – Meta-analysis RCTs
Quigley, M., et al. (2022) – Mitochondrial + mTOR regulation
Muñoz, A., & Grant (2022)
Marigoudar, J. B., et al. (2022)
Sheeley, M. P., et al. (2022)
Seraphin, G., et al. (2023)
5. Zinc, Minerals & Trace Elements
Tamai, Y., et al. (2020) – Zinc biomarkers in HCC
Yokokawa, H., et al. (2020) – Zinc deficiency epidemiology
Chen, M., et al. (2020) – Zinc ionophore anticancer
Wu, S., et al. (2022) – Zinc metabolic targeting
Ye, H., et al. (2022) – Zinc nanoparticles + chemo resistance
Hoppe, C., et al. (2021) – Systematic review (clinical relevance)
Li, J., et al. (2022) – Umbrella review
Gelbard, A. (2022)
Sugimoto, R., et al. (2024)
6. Hyperbaric Oxygen Therapy (HBOT)
Hadanny, A., et al. (2022) – RCT (mitochondrial respiration)
Liu, X., et al. (2021) – Tumor microenvironment + drug delivery
Xiong, Y., et al. (2023) – Cancer stem cell elimination
7. Cancer Stem Cells & Tumor Microenvironment
Zhou, H.-M., et al. (2021) – Targeting CSCs
Praharaj, P. P., et al. (2022) – Mitophagy & CSCs
Zheng, X. X., et al. (2023) – Mitochondria in CSCs
Hillers-Ziemer, L. E., et al. (2020) – Obesity + CSC interaction
Jariyal, H., et al. (2021) – Stemness biology
8. Exercise, Lifestyle & Metabolism
Bull, F. C., et al. (2020) – WHO physical activity guidelines
Wang, Q., & Zhou (2021) – Exercise in cancer
Kolodziej & O’Halloran (2021) – Oxidative phenotype
Liu, C., et al. (2023) – Exercise & regeneration
9. General Oncology, Trials & Systems
Del Paggio, J. C., et al. (2021) – RCT evolution
Ladanie, A., et al. (2020) – FDA approvals evidence
Wei, Q., et al. (2020) – Metabolic rewiring
Sia, J., et al. (2020) – Radiation mechanisms
10. Emerging / Miscellaneous Metabolic & Adjunct Therapies
Rais, R., et al. (2022) – Metabolic inhibitor (DRP-104)
van den Boogaard, W. M. C., et al. (2022) – Chemo toxicity biology
Suwannasom, N., et al. (2020) – Riboflavin review
.png)
.png)
Comments
Post a Comment